Slide 1: Earnings Call Presentation (Jun'25 Qtr.)
Earnings Call Presentation (Jun’25 Qtr.) (1/8/25)
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements which may be identified by their use of words like “plans,” “expects,” “will,” “anticipates,” “believes,” “intends,” “projects,” “estimates” or other words of similar meaning. All statements that address expectations or proj
Slide 3: Table of Content
Table of Content ► Standalone Financials Overview ► Consolidated Financial Snapshot ► Strategic Outlook & Way Forward 3
Slide 4: Standalone Financials Overview
Standalone Financials Overview
Slide 5: Standalone Financials: Jun'25 v/s Jun'24
Standalone Financials: Jun’25 v/s Jun’24 (₹ Cr.) YoY ▲ / ▼ Particulars Jun’24 Jun’25 (%) Revenue weighed down by – ► Shortened and rain-disrupted summer Revenue from operations 373 229 (-39%) ► Early onset of monsoon ► High-base of Jun’24 qtr. accentuated it further Gross Margin 197 116 (-41%) Secon
Slide 6: Standalone TTM Financials: Jun'25 v/s Jun'24
Standalone TTM Financials: Jun’25 v/s Jun’24 (₹ Cr.) Revenue from operations Gross Margin EBITDA PBT (Before Exceptional Items) 1,038 508 229 283 v/s 996 (▲4%) v/s 498 (▲2%) v/s 236 (▼3%) v/s 275 (▲3%) 48.9% (1.1%) 22.0% (1.6%) 27.2% (0.4%) Capital Employed in ROCE (%) RONW (%) Treasury Core Busi
Slide 7: Consolidated Financials Snapshot
Consolidated Financials Snapshot
Slide 8: Consol. Financials (Continuing Operations): Jun'25 v/s Jun'24
Consol. Financials (Continuing Operations): Jun’25 v/s Jun’24 (₹ Cr.) Symphony GSK SCL Consol. ^ YoY ▲ / ▼ Particulars India China Brazil (Continuing) (%) Revenue from operations 229 24 1 251 (-36%) Gross Margin 116 8 (-0) 125 (-40%) EBITDA 24 2 (-1) 26 (-71%) PAT 37 1* (-0) 39 (-47%) Gross Margin (
Slide 9: Consol. Financials (Discontinued Operations): Jun'25 v/s Jun'24
Consol. Financials (Discontinued Operations): Jun’25 v/s Jun’24 (₹ Cr.) IMPCO Symphony AU Consol. ^ YoY ▲ / ▼ Particulars Mexico Australia (Discontinued) (%) Revenue from operations 66 58 99 (-28%) Gross Margin 24 23 44 (-32%) EBITDA 7 6 12 (-50%) PAT 4 (-2) 3 (-79%) Gross Margin (%) 35.8% 39.4% 44.
Slide 10: Status of IPR Transaction between GSK and IMPCO
Status of IPR Transaction between GSK and IMPCO GSK transferred technology know-how and nine IPRs to IMPCO GSK China IMPCO Mexico USD 5.2 Million (~ ₹ 44 cr.) Monetized them (specifically Beneficial even for IMPCO’s First tranche (~ ₹ 22 cr.) developed for IMPCO), monetization, while completed; bala
Slide 11: Strategic Outlook & Way Forward
Strategic Outlook & Way Forward
Slide 12: Strategic Outlook & Way Forward
Strategic Outlook & Way Forward ‘Air Force’ Range ‘Air Force’ range of air coolers launched – Gaining Altitude ► Strong traction fueling scale-up and range expansion Accelerating all-season and counter-seasonal product- led growth, leveraging brand-led innovation & distribution Enhancing Portfolio ►
Slide 13: Glossary
Glossary Gross Margin (%) : % of Revenue from operations A&P Expenses : Advertisement and Sales Promotion Expenses : Earnings Before Interest, Tax, Depreciation and Amortization EBITDA (Excludes Other Income, Exceptional Items and Foreign Exchange Loss incl. MTM) EBITDA Margin (%) : % of Revenue fro
Slide 14: Thank You
Thank You \ | Master Cool! Arctic Circle | Hi | = BONAIRE | Durango | OtravelAire